Institutional Investor Files Form 144 to Sell Over $8M in Sionna Therapeutics Stock
SION has more than doubled off its 52-week low of $7.255 on elevated volume (2.3× avg).
Summary
Rise Fund Sling, L.P., a significant stockholder, has filed a Form 144 indicating its intent to sell 195,667 shares of Sionna Therapeutics common stock, valued at approximately $8.17 million.
Key Events · Ownership and Investor Activity · SION
-
Intent to Sell Shares
Rise Fund Sling, L.P. filed a Form 144 to sell 195,667 shares of common stock.
-
Significant Transaction Value
The proposed sale has an approximate market value of $8.17 million.
-
Prior Sales Activity
This filing follows previous Forms 144 from related entities for an aggregate of 250,000 shares sold in the last three months.
Analysis · SION · Life Sciences
This Form 144 filing by Rise Fund Sling, L.P., an institutional stockholder, signals an intent to sell a substantial block of shares. While institutional sales can be for portfolio rebalancing, the proposed sale of over $8 million, combined with previous filings for aggregate sales of 250,000 shares in the past three months from related entities, suggests a notable reduction in their stake. This could create an overhang on the stock as the market absorbs the selling pressure.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 29.1% of the 1683 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.32%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SION was trading at $42.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $7.26 to $45.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.